2025 SABCS Highlights: First-Line Tx for HER2+ Advanced Breast Cancer | Dana-Farber Cancer Institute

30 Visioni

  • Grazie! Condividilo con i tuoi amici!

    Non hai gradito questo video. Grazie per il feedback!

admin
Published
Harold Burstein, MD, PhD, and Sarah Sammons, MD, discuss the DESTINYBreast09, HER2-CLIMB, and PATINA CNS trials for first-line treatment in advanced breast cancer, which were presented at the 2025 San Antonio Breast Cancer Symposium.

For more information about Dana-Farber's Breast Oncology Center, visit https://www.dana-farber.org/cancer-care/treatment/breast-oncology
Categoria
Oncology
Commenta per primo questo video.

Prossimo